Benutzer: Gast  Login
Titel:

The first targeted therapy in ovarian cancer permitted for BRCA1/2 mutation carriers

Dokumenttyp:
Article
Autor(en):
Schmutzler, RK; Meindl, A
Abstract:
Olaparib (Lynparza (TM)) is an oral, small-molecule, poly (ADP-ribose) polymerase (PARP) inhibitor being developed by AstraZeneca for the treatment of solid tumours. The primary indication for which olaparib is being developed is BRCA1/2 mutation-positive ovarian cancer. A capsule formulation of the drug has received approval for use in this setting in the EU by the European Medicines Agency (EMA). The application of olaparib has been indicated for germline and somatic mutations in BRCA1 and/or...     »
Zeitschriftentitel:
Med. Genet.
Jahr:
2015
Band / Volume:
27
Heft / Issue:
2
Seitenangaben Beitrag:
228-230
Sprache:
de
Print-ISSN:
0936-5931
TUM Einrichtung:
Frauenklinik und Poliklinik
 BibTeX